Xintela (XINT.ST) Stock Analysis & AI Equity Report
Xintela (XINT.ST) overview
Xintela (XINT.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Xintela reported revenue of SEK 2.3m and operating profit of SEK -46.7m; the year-end share price was 0.28 SEK and market capitalisation was SEK 196m. Xintela is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Xintela's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Xintela
Xintela AB is a clinical-stage biopharma company developing stem cell therapies and targeted cancer therapies based on its integrin alpha10beta1 platform. Its main programs include the XSTEM stem cell product for osteoarthritis and difficult-to-heal wounds, manufacturing and process development through its GMP facility, and antibody-based oncology candidates under its Targinta subsidiary.
Generate the Xintela report
Xintela is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Xintela and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.